Statins and hormone therapy: effects on blood clotting in menopausal women with high cholesterol
Observes how statins affect blood clotting in menopausal women on hormone therapy.
Plain-language title generated from the registry record
Registry title: Effects of Statins and Hormone Replacement Therapy in Coagulation Profile of Menopausal Women With Dyslipidemia
Key facts
- Where
- Pisa, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 55 years old?
Source: NCT07742488, who can take part
Where in Italy
- Santa Chiara Hospital - University Hospital of PisaPisa, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Pisa
- Trial code
- NCT07742488
- Record updated
- 3 August 2026
- Original description
The goal of this study is to understand whether statin therapy, a common lipid-lowering therapy, may improve the coagulation profile of menopausal women with hypercholesterolemia undergoing hormone replacement therapy with oral estroprogestin. It will also learn about the liver safety of the combination. The main questions will be:Read full original descriptionShow less
The Role of STAtins in Reversing Coagulation Profile Changes Induced by Hormone Replacement Therapy in Menopausal Women With Hypercholesterolemia: the STAR-HRT Study
The goal of this study is to understand whether statin therapy, a common lipid-lowering therapy, may improve the coagulation profile of menopausal women with hypercholesterolemia undergoing hormone replacement therapy with oral estroprogestin. It will also learn about the liver safety of the combination. The main questions will be:
1. does hormone replacement therapy affect the coagulation profile? 2. when we add statin therapy due to hypercholesterolemia not improving with lifestyle, does it reverse eventual changes of the coagulation profile occurred after initiation of hormone replacement therapy? 3. do the two therapies have an effect on overall inflammation of the organism?
Participants will be asked to participate to the study before starting any therapy, if they need hormone relacement therapy due to symptoms, if they have a new onset of dyslipidemia and if they do not have contraindications to the therapies object of the study. The study is observational, thus it will not affect in any way the clinical care, which will follow only guidelines. During routine blood sample collection, additional aliquotes will be taken for the study at the recruitment, after 3 months of hormone replacement therapy and lifestyle changes, at the end of the study (after one year from the recruitment).
Inclusion: Women aged between 45 and 55; Early postmenopausal period (within 5 years of the last menstrual cycle); Prescription of oral estrogen-progestin HRT for symptoms that require it according to current guidelines; Low-moderate cardiovascular risk (SCORE2 calculation and assessment based on age); LDL levels above target according to the class of risk.
Exclusion: Ongoing therapies that interfere with the study objectives: HRT or other estroprogestin therapy, lipid-lowering drugs, anticoagulants, or antiplatelet agents; Current or previous venous or arterial thrombotic event; Diagnosis of cancer for which treatment is ongoing or has been discontinued for less than 10 years; Chronic inflammatory bowel disease; Diabetes mellitus; Acute/chronic liver failure or abnormal liver enzymes (ALT or AST > 100 IU/L; GGT > 100 IU/L; alkaline phosphatase > 250 IU/L); Recent pregnancy (<1 year) or current breastfeeding; Known hereditary thrombophilia; Body mass index (BMI) > 30 kg/m²; Other known risk factors for VTE or contraindications to HRT; Refusal to take HRT.